2024年

December 16, 2024: KYORIN and Bayer Enter into License Agreement for Novel Obstructive Sleep Apnea (OSA) Treatment
December 6, 2024: Notice of the relocation of the Nishinihon Distribution Center
November 7, 2024: Presentation document for Fiscal 2024 1st half (interim period) financial results
November 7, 2024: Consolidated Financial Results for the Six Months Ended September 30, 2024) [Japanese GAAP]
November 7, 2024: Consolidated Financial Results for Second Quarter (Interim Period) of FY2024 - Supplementary Information
November 7, 2024: Notice Regarding difference between financial forecast and actual results
August 2, 2024: Option Agreement for drug discovery of extracellular vesicles derived from airway epithelial cells
July 31, 2024: 1Q Consolidated Financial Results for the Fiscal Year Ending March 31, 2025 (September 31, 2024) - Supplementary Information
July 31, 2024: Summary of Consolidated Financial Results(For the first quarter ended June 30, 2024) [Japanese GAAP]
May 21, 2024: Notice of Dividends of Retained Earnings
May 10, 2024: Summary of Consolidated Financial Results(For fiscal year ended March 31, 2024) [Japanese GAAP]
May 10, 2024: Consolidated Financial Results for the Fiscal Year Ended March 31, 2024 (May 10 2024) - Supplementary Information
April 15, 2024: Starting Date of Operation at the New Head Office
February 6, 2024: Summary of Consolidated Financial Results(For third quarter ended December 31, 2023) [Japanese GAAP]
February 6, 2024: Third Quarter Consolidated Financial Results for the Fiscal Year Ending March 31, 2024 (Feb 6, 2024) - Supplementary Information
January 22, 2024: Kyorin and Veneno conclude Joint Research Agreement for Functional DRPs